Addario Lung Cancer Medical Institute - ALCMI

01/17/2026

Christian Jobin, Ph.D., and Rachel Newsome, Ph.D., at UF Health Cancer Institute have identified a gut microbiota–derived metabolite, Bac429, that materially increases immunotherapy activity in lung cancer models and is now being advanced into a drug candidate.

GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…

01/16/2026

Catherine Sears, MD, and colleagues at Indiana University are linking impaired DNA repair to the shared biology of emphysema and lung cancer.

Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.

01/15/2026

Zoldonrasib just became the first investigational KRAS G12D targeted therapy in NSCLC to receive FDA Breakthrough Therapy Designation, based on Phase 1 monotherapy data from Revolution Medicines.

01/14/2026

Basal stem cells, not neuroendocrine cells, may be the initiating cell of origin for small-cell lung cancer, according to Trudy Oliver.

The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — long-lived cells that help repair and replace damaged tissue in the lungs — contradicting what scientists have thought for decades.

01/13/2026

Olvi-Vec delivered durable systemic activity in platinum-relapsed lung cancer, with up to 85% tumor shrinkage reported by Genelux in interim trial data published by RTTNews.

01/12/2026

Six FDA approvals in December 2025 expanded the oncology toolbox across blood cancers, prostate cancer, lung cancer, and supportive care, as reported in Cure.

The FDA approved six new therapies for blood, prostate and lung cancers and supportive care, expanding treatment options based on recent trials.

01/11/2026

Check this out! AstraZeneca is re-running Datroway in relapsed NSCLC with a biomarker-enriched phase 3 design that directly addresses the Tropion-Lung01 miss.

Data insights Datroway’s Tropion-Lung01 do-over? 2 January 2026   Jacob Plieth   AstraZeneca, still awaiting the key catalyst of Datroway’s Avanzar study readout, recently took this TROP2-targeting ADC into a phase 3 trial in the tough setting of relapsed non-small cell lung cancer. The trial ...

01/10/2026

A large-scale study from the Genetic Epidemiology of Lung Cancer Consortium, led by Yanhong Liu and published in the Journal of Thoracic Oncology, identifies rare, high-penetrance germline variants that materially elevate familial lung cancer risk.

01/09/2026

Inflammation is emerging as a primary engine of progression in small cell lung cancer.

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to chemotherapy. However, patients typically relapse and experience very rapid disease progression. Current re...

01/08/2026

Early-onset lung cancer incidence in the United States is falling overall, but not for lung adenocarcinoma in young Asian and Hispanic women, according to a new SEER-based analysis.

Lung cancer incidence among adults aged 20–49 years in the United States declined overall from 2000 to 2021 across histologic subtypes and demographic groups. Declines were less pronounced among Hisp...

01/07/2026

LEMS in small cell lung cancer remains under-recognized and frequently misattributed to treatment-related toxicity, as highlighted by our friend Dr. Jacob Sands, MD, in a recent OncLive commentary.

Jacob Sands, MD, discusses challenges in the diagnosis and management of LEMS in patients with small cell lung cancer.

01/06/2026

A new phase 3 report in the NEJM Group shows that adding platinum-pemetrexed chemotherapy to first-line osimertinib improves overall survival in EGFR-mutated advanced NSCLC.

Combination chemotherapy has long been a mainstay of cancer treatment, although early mechanism-based therapies showed little promise. In 1970, Vincent T. DeVita and colleagues revolutionized oncol...